Table 3.
Unadjusted and Adjusted Hazards Ratios for CNS endpoint by HLA Alleles.
| Alleles | Comparisons | Unadjusted HR (95%CI) | p-value | Adjusteda HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value |
|---|---|---|---|---|---|---|---|
| A | homozygotes vs. heterozygotes | 0.90 (0.40,2.00) | 0.79 | 2.88 (0.53,15.50) | 0.22 | 0.99 (0.44,2.22) | 0.98 |
| B | homozygotes vs. heterozygotes | 1.33 (0.63,2.81) | 0.45 | 1.64 (0.49,5.44) | 0.42 | 1.35 (0.63,2.91) | 0.44 |
| C | homozygotes vs. heterozygotes | 1.25 (0.66,2.39) | 0.5 | 0.83 (0.28,2.45) | 0.73 | 1.34 (0.70,2.58) | 0.38 |
| DRB1 | homozygotes vs. heterozygotes | 1.67 (0.93,3.01) | 0.09 | 1.77 (0.68,4.58) | 0.24 | 1.82 (1.00,3.29) | 0.05 |
| A-1 | presence vs. absence | 1.59 (0.93,2.72) | 0.09 | 1.03 (0.32,3.31) | 0.97 | 1.66 (0.96,2.86) | 0.07 |
| A-24 | presence vs. absence | 2.01 (1.04,3.88) | 0.04 | 2.84 (0.76,10.64) | 0.12 | 2.04 (1.07,3.89) | 0.03 |
| B-27 | presence vs. absence | - | *<0.0001 | - | - | - | - |
| B-57 | presence vs. absence | 0.68 (0.27,1.71) | 0.42 | 0.35 (0.04,2.79) | 0.32 | 0.62 (0.23,1.66) | 0.34 |
| Cw-5 | presence vs. absence | 1.78 (0.93,3.42) | 0.08 | 4.76 (1.52,14.90) | 0.01 | 1.96 (1.01,3.79) | 0.05 |
| DQB1-2 | presence vs. absence | 0.58 (0.36,0.93) | 0.02 | 0.53 (0.21,1.34) | 0.18 | 0.61 (0.37,0.99) | 0.04 |
a
Adjusted for baseline covariates: race, gender, age, baseline log HIV-1 RNA, change of log HIV-1 RNA from baseline to week 24 and 48, baseline CD4+ lymphocyte count and percent, change of CD4+ lymphocyte count from baseline to week 24 and 48, Baseline WAZ Score and treatment.
b
Adjusted for other genotypes: CX3CR1-280-T/M, SDF-1-180-G/A, and MBL2-P/Q
*
The p-value is from the robust score test of the Cox model in order to account for the sampling weight in the variance estimation. Since none of the subjects possessing the B-27 allele was observed to have a CNS endpoint during follow-up, no HR and 95% CI estimates can be calculated.